Juan Andres, Director of Technical Operations and Quality of Moderna, elected to the National Academy of Engineering


News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

CAMBRIDGE, Mass. / ACCESSWIRE / February 9, 2022 / Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Juan Andres, Director of Technical Operations and Quality, has been elected to the National Academy of Engineering (NAE), widely recognized as one of the highest recognitions of achievement in the field of engineering.

“We are delighted that the National Academy of Engineering has recognized Juan for his outstanding contributions. Juan has led our manufacturing from an early-stage clinical development company to a commercial company,” said Stephane Bancel, President and CEO of Moderna. “In our first year of commercial operation, he led the manufacturing, quality control and distribution of over 800 million doses of our COVID-19 vaccine globally, all in the midst of a pandemic. For context, we manufactured less than 100,000 doses in 2019. . That’s an incredible increase in two years. We, and the hundreds of millions of people around the world who have received the Moderna COVID-19 vaccine, owe Juan our gratitude. I am grateful to have him as a member of the Moderna Committee executive and to count him as a partner and a friend.”

Juan was cited by the NAE for his “technical leadership in scaling up and manufacturing important pharmaceuticals, including the mRNA-1273 COVID vaccine.” Responsible for sourcing products required for Moderna’s preclinical and clinical development programs, as well as scaling CMC (Chemistry, Manufacturing and Controls) processes across Moderna’s portfolio. Juan leads all of CMC’s late-stage development and commercialization activities for Moderna’s COVID-19 vaccine, Spikevax®, and its extensive pipeline of 40 development programs.

In his role at Moderna, Juan leads the rapid scale-up of manufacturing for Spikevax. In 2021, Moderna shipped approximately 807 million doses of Spikevax to countries around the world. Today, Juan’s team has grown to more than 1,500 from 350 at the end of 2019, when Moderna was manufacturing fewer than 10,000 doses per month. Moderna has also expanded its global manufacturing footprint, expanding its Massachusetts-based technology center campus and establishing strategic manufacturing partnerships in Switzerland, Spain, the Netherlands, France and South Korea.

Juan was previously responsible for global technical operations (manufacturing and supply chain) for more than 25,000 Novartis employees across all of its divisions. In this role, he was responsible for all Novartis manufacturing sites and related supporting functions and technologies worldwide, overseeing drug substance and small molecule drug product, as well as biologic drug substance, drug product and technical development. Previously, Juan held the positions of Novartis Group Quality Manager, Global Head of Technical Research and Development and Head of Global Pharmaceutical Operations. Prior to Novartis, he worked at Eli Lilly & Co. for 18 years in various manufacturing, production and quality roles in the US, Puerto Rico, UK and Spain, most recently serving as vice -president of pharmaceutical manufacturing.

The latest NAE peer elections bring the Academy’s total American membership to 2,388, plus 310 international members. The mission of the NAE is “to advance the welfare of the nation by promoting a vibrant engineering profession and by bringing together the expertise and ideas of eminent engineers to provide independent advice to the federal government on matters involving engineering and technology”.

For more information on the NAE, please visit their website at https://www.nae.edu/.

About Moderna

In the 10 years since its inception, Moderna has grown from a scientific research company advancing programs in the field of messenger RNA (mRNA) to a company with a diverse clinical portfolio of vaccines and therapeutics in seven modalities, a broad portfolio of intellectual property in areas such as mRNA and lipid nanoparticle formulation, and an integrated manufacturing facility that enables large-scale clinical and commercial production at unprecedented speed. Moderna maintains alliances with a wide range of domestic and foreign government and commercial collaborators, which has enabled the pursuit of both breakthrough science and rapid scale-up of manufacturing. More recently, Moderna’s capabilities have come together to enable licensed use of one of the oldest and most effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform leverages continuous advancements in basic and applied mRNA science, delivery technology and manufacturing, and has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named one of Science’s Top Biopharmaceutical Employers for the past seven years. To learn more, visit www.modernatx.com.

Moderna Contacts

Colleen Hussey
Director, Corporate Communications

Lavina Talukdar
Senior Vice President and Head of Investor Relations

THE SOURCE: Moderna, Inc.

See the source version on accesswire.com:


Comments are closed.